Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out
D. Wilbie, S. Eising, V. Amo-Addae, J. Walther, E. Bosman, O. G. de Jong, J. J. Molenaar, E. Mastrobattista
This study screens cancer drugs to find those that enhance HDR over NHEJ in CRISPR gene editing, identifying Aurora kinase A inhibitors as promising candidates.
PLOS One · Sep 26, 2025Peer-reviewedPharmacology & Toxicology